机构：[1]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China四川省肿瘤医院[2]The Third People’s Hospital of Sichuan Province, Chengdu, China四川省人民医院
Radiotherapy-induced oral mucositis is the most common side effect in nasopharyngeal carcinoma (NPC) patients. We aimed to evaluate the efficacy and safety of Rabdosia rubescens drop pills in NPC patients with radiation-induced oral mucositis (RTOM).The study involved 40 NPC patients who were given Rabdosia rubescens drop pills thrice daily from the start of radiation therapy. The study monitored the incidence and severity of oral mucositis and oral pain. The main outcomes measured were the occurrence rate of oral mucositis, grade 3 oral mucositis, oral pain assessment, and changes in immunological function, body weight, BMI, NRS2002, and albumin levels.In the study, 38 patients completed the treatment. The incidence rates of Grade 0 to 3 oral mucositis were 5.26%, 21.05%, 47.37%, and 26.32% respectively. Pain levels were mild (42.11%), moderate (13.16%), and severe (13.16%). The onset of Grade 1, 2, and 3 oral mucositis occurred at 18, 24, and 30 days respectively. Grade 3 oral mucositis was associated with body weight, BMI, NRS2002 score, and albumin levels. Post-treatment, there was a decrease in CD4+/CD8+, CD3+, and CD4+ immune cells, but an increase in CD8+ cells. Mild to moderate gastrointestinal adverse events were observed in 13.2% of patients.Rabdosia rubescens drop pills administration can reduce the incidence and severity of radiotherapy induced oral mucositis. Our finding suggested a positive impact of Rabdosia rubescens drops pills upon administration to NPC patients.
基金：
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
This research was funded by the Sichuan Province Science
and Technology Program (No. 2021JDRC0146); Sichuan
Province Science and Technology Program (No. 2022YFS0047);
Oncology Medicine and Engineering Innovation Fund (No.
ZYGX2021YGCX006); Sichuan Province Science and
Technology Program (No. 2020YFS0424); and Sichuan Medical
Association Project (No. 20210221020001)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类|3 区医学
小类|3 区全科医学与补充医学4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
通讯作者：
通讯机构：[1]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China[2]The Third People’s Hospital of Sichuan Province, Chengdu, China
推荐引用方式(GB/T 7714)：
Li Lu,Huang Yecai,Yin Jun,et al.The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study[J].Integrative Cancer Therapies.2025,24:15347354251314499.doi:10.1177/15347354251314499.
APA：
Li Lu,Huang Yecai,Yin Jun,Xu Peng,Lan Mei...&Feng Mei.(2025).The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study.Integrative Cancer Therapies,24,
MLA：
Li Lu,et al."The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study".Integrative Cancer Therapies 24.(2025):15347354251314499
